Cane Capital Partners’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY
Cane Capital Partners's BMY Position: Q2 2026 in Review
Cane Capital Partners increased its Bristol-Myers Squibb (BMY) stake by 121% in Q2 2026, buying an estimated $600K and bringing the position to 19,059 shares worth $1.1M. The position accounts for 0.43% of the portfolio, ranked #57.
Cane Capital Partners first reported a position in BMY in Q4 2025 and has held it in 3 quarters since. 2,502 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Cane Capital Partners held 19,059 shares of Bristol-Myers Squibb worth $1.1M as of Q2 2026.
- Cane Capital Partners bought 10,450 Bristol-Myers Squibb shares in Q2 2026, an estimated $600K.
- Bristol-Myers Squibb made up 0.43% of Cane Capital Partners's portfolio in Q2 2026, its #57 holding.
- Cane Capital Partners first reported a position in Bristol-Myers Squibb in Q4 2025 and has held it in 3 quarters since.
- 2,502 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Cane Capital Partners's 13F filing for Q2 2026, filed 5 Aug 2026.